Target type: molecularfunction
Binding to a CCR2 chemokine receptor. [GOC:mah, GOC:nln]
CCR2, a member of the G protein-coupled receptor (GPCR) family, plays a critical role in mediating the inflammatory response by binding to its ligands, the chemokines CCL2 (MCP-1), CCL7 (MCP-3), CCL8 (MCP-2), and CCL13 (MCP-4). Upon binding, CCR2 activates intracellular signaling cascades, primarily involving the Gαi protein, leading to downstream effects like cytoskeletal rearrangements, chemotaxis, and leukocyte activation. The molecular function of CCR2 chemokine receptor binding involves the following steps:
1. Ligand Binding: The chemokine ligand binds to the extracellular domain of CCR2, specifically to the N-terminal region and the first extracellular loop. This binding event induces conformational changes in the receptor.
2. G Protein Coupling: The conformational changes in CCR2 trigger the recruitment and activation of the Gαi protein. This protein is a heterotrimeric complex consisting of Gα, Gβ, and Gγ subunits.
3. Signaling Cascade Initiation: Activated Gαi protein dissociates from the Gβγ dimer and interacts with downstream signaling molecules, such as phospholipase C (PLC).
4. Second Messenger Production: PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3). DAG activates protein kinase C (PKC), while IP3 increases intracellular calcium levels.
5. Cellular Responses: The activation of these signaling pathways ultimately leads to a series of cellular responses, including:
- Chemotaxis: CCR2 binding to its ligands induces directional migration of leukocytes towards the source of the chemokine.
- Cytoskeletal Rearrangements: CCR2 activation leads to reorganization of the actin cytoskeleton, which is essential for cell movement and adhesion.
- Leukocyte Activation: CCR2 signaling promotes leukocyte activation, resulting in the release of inflammatory mediators and the upregulation of surface receptors involved in immune responses.
6. Receptor Desensitization: Prolonged activation of CCR2 leads to receptor desensitization, a process that limits excessive signaling. This involves the phosphorylation of the receptor by G protein-coupled receptor kinases (GRKs), followed by the binding of β-arrestin, which uncouples the receptor from the signaling cascade.
In summary, CCR2 chemokine receptor binding initiates a complex signaling cascade involving G protein coupling, second messenger production, and the activation of downstream signaling molecules, culminating in chemotaxis, cytoskeletal rearrangements, and leukocyte activation.'
"
Protein | Definition | Taxonomy |
---|---|---|
C-C chemokine receptor type 2 | A C-C chemokine receptor type 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P41597] | Homo sapiens (human) |
C-C motif chemokine 2 | A C-C motif chemokine 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P13500] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
disulfiram | organic disulfide; organosulfur acaricide | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor | |
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
nifedipine | Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent |
dibenzothiazyl disulfide | dibenzothiazol-2-yl disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of two molecules of 1,3-benzothiazole-2-thiol. It is used as an accelerator in the rubber industry. dibenzothiazyl disulfide: vulcanizing accelerant | benzothiazoles; organic disulfide | allergen |
1-naphthylisothiocyanate | 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage. | isothiocyanate | insecticide |
plerixafor | plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2 | azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound | anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant |
rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
fasudil hydrochloride | fasudil hydrochloride : A hydrochloride obtained by reaction of fasudil with one equivalent of hydrochloric acid. | hydrochloride | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; neuroprotective agent; nootropic agent; vasodilator agent |
tak 779 | |||
y 27632 | Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme. | aromatic amide | |
ha 1100 | HA 1100: intracellular calcium antagonist | ||
bay 11-7085 | BAY11-7085 : A sulfone that is benzene substituted by [(E)-2-cyanoethenyl]sulfonyl and tert-butyl groups at position 1 and 4, respectively. It is an irreversible inhibitor of IkappaB-alpha phosphorylation in cells (IC50 = 10 muM) and prevents the activation of NF-kappaB. | benzenes; nitrile; sulfone | anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor |
ucb 35625 | UCB 35625: J-113863 is the (trans)-isomer; structure in first source | ||
rs 504393 | RS 504393: structure in first source | 1,3-oxazoles | |
incb3344 | INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist | ||
amd 070 | mavorixafor: a derivative of AMD3100; a CXCR4 blocker | aminoquinoline | |
cenicriviroc | cenicriviroc : A member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). cenicriviroc: an inhibitor of HIV-1 | aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide | anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist |
incb 3284 | INCB 3284: a CCR2 receptor antagonist | ||
azd8309 | AZD8309: CXCR2 inhibitor | ||
n-(carbamoylmethyl)-3-trifluoromethyl benzamido-4-chlorobenzyl 3-aminopyrrolidine |